Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Recent Clinical Research on Nonalcoholic Fatty Liver Disease: 2nd Edition
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Recent Clinical Research on Nonalcoholic Fatty Liver Disease: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 20 January 2026 | Viewed by 3875

Special Issue Editor

Dr. Gerond V. Lake-Bakaar

E-Mail Website
Guest Editor
Transplant Center, Presbyterian Saint Luke's Medical Center, Denver, CO 80218, USA
Interests: hepatitis; liver cirrhosis; alcoholic liver disease; liver failure; nonalcoholic steatohepatitis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is my pleasure to invite you to contribute to the Special Issue entitled “Recent Clinical Research on Nonalcoholic Fatty Liver Disease: 2nd Edition”. We published seven papers in the first volume and this is a new volume of this Special Issue. For more details, please visit: https://www.mdpi.com/journal/jcm/special_issues/39EPKBNY7D.

The last decade saw enormous progress in our ability to treat and control chronic hepatitis C virus liver disease. In more recent years, nonalcoholic fatty liver disease (NAFLD) has emerged as a significant cause of liver disease, affecting millions worldwide. This chronic condition is characterized by the build-up of fat in the liver, which can lead to inflammation, fibrosis, and even cirrhosis. While the traditional risk factors for liver disease, such as hepatitis C, have declined due to effective treatment and prevention measures, NAFLD has become more prevalent due to changes in lifestyle and diet.

In this Special Issue, we welcome authors to submit papers on the global changes in disease prevalence. Clinical advances in the diagnoses; factors associated with disease progression; and the results of ongoing trials and advances in disease treatment are encouraged.

Dr. Gerond V. Lake-Bakaar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • NAFLD
  • NASH
  • cirrhosis
  • hepatocellular carcinoma
  • hepatitis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 658 KB  
Article
Exploring the Prevalence and Risk Factors of MASLD in Patients with Newly Diagnosed Diabetes Mellitus: A Comprehensive Investigation
by Hatice Beyazal Polat, Mehmet Beyazal, Medeni Arpa, Bayram Kızılkaya, Teslime Ayaz, Ömer Lütfi Gündoğdu, Kamil Konur, Zehra Polat, Fatma Beyazal Çeliker and Halil Atasoy
J. Clin. Med. 2025, 14(10), 3513; https://doi.org/10.3390/jcm14103513 - 17 May 2025
Cited by 1 | Viewed by 1497
Abstract
Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) represents a growing concern in the context of metabolic disorders, particularly among individuals diagnosed with type 2 diabetes mellitus (T2DM). This study aimed to investigate the prevalence of MASLD among newly diagnosed T2DM patients and identify [...] Read more.
Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) represents a growing concern in the context of metabolic disorders, particularly among individuals diagnosed with type 2 diabetes mellitus (T2DM). This study aimed to investigate the prevalence of MASLD among newly diagnosed T2DM patients and identify the risk factors for MASLD in this population. Methods: This prospective study included 128 patients with newly diagnosed T2DM between January 2022 and June 2023. Demographic, clinical, anthropometric (BMI, waist circumference), and laboratory data (glucose, HbA1c, lipid profile, ALT, AST, creatinine, platelet count) were collected. MASLD was diagnosed based on ultrasonographic evidence of hepatic steatosis with at least one cardiometabolic risk factor after excluding other causes. Linear regression models were used to determine independent predictors. Results: MASLD was detected in 80.4% of patients. Compared with the MASLD (−) group, the MASLD (+) group had significantly higher ALT (47.1 ± 23 U/L vs. 24.9 ± 8 U/L, p < 0.001) and non-HDL cholesterol (189 ± 57 mg/dL vs. 167 ± 28 mg/dL, p = 0.047). Spearman correlation showed positive associations of MASLD severity with waist circumference, LDL cholesterol, and platelet count. ALT and BMI were independently associated with MASLD in linear regression analysis. Conclusions: This study underscores the significant prevalence of MASLD in newly diagnosed T2DM patients, emphasizing the relevance of early detection in addressing this common comorbidity in the diabetic population. Full article
(This article belongs to the Special Issue Recent Clinical Research on Nonalcoholic Fatty Liver Disease: 2nd Edition)
►▼ Show Figures

Figure 1

12 pages, 2705 KB  
Article
Persistently Active Helicobacter pylori Infection Is Associated with the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease
by Jun Young Kim, Byung Soo Kwan, Jung Hwan Cho, Hye In Kim, Nak Gyeong Ko, Mihyeon Jin and Ok Jae Lee
J. Clin. Med. 2025, 14(4), 1073; https://doi.org/10.3390/jcm14041073 - 7 Feb 2025
Cited by 3 | Viewed by 1649
Abstract
Background/Objectives: Previous studies suggested a link between Helicobacter pylori (H. pylori) infection and steatotic liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to identify the association of active H. pylori infection and the new concept of MASLD [...] Read more.
Background/Objectives: Previous studies suggested a link between Helicobacter pylori (H. pylori) infection and steatotic liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to identify the association of active H. pylori infection and the new concept of MASLD in a longitudinal cohort. Methods: We reviewed 1497 health examinees who had two endoscopic biopsies for H. pylori activity without hepatic steatosis at the baseline abdominal ultrasonography. Subjects were classified into four groups based on H. pylori activity. Multivariable Cox models assessed the link between active H. pylori infection status and incident MASLD. Results: Over a median follow-up of 31.1 months, 247 subjects (16.5%) developed MASLD. The groups were: H. pylori naïve (n = 57, 15.6%), de novo (n = 31, 15.3%), eradicated (n = 32, 16.1%), and persistent (n = 127, 17.4%). The H. pylori persistent group had a higher risk of MASLD compared to naïve group (hazard ratio: 1.41; 95% confidence interval: 1.01–1.96; p-value = 0.045). The association between H. pylori infection and incident MASLD was significant only with ongoing infection. Conclusions: Persistent H. pylori infection increases the risk of MASLD, indicating that active infection may contribute to MASLD development. Eradicating active H. pylori infection might help lower the incidence of MASLD. Full article
(This article belongs to the Special Issue Recent Clinical Research on Nonalcoholic Fatty Liver Disease: 2nd Edition)
►▼ Show Figures

Figure 1

Other

Jump to: Research

18 pages, 1646 KB  
Systematic Review
Meta-Analysis of AI Integration in Abdominal Imaging for Liver Fibrosis and MASLD: Evaluating Diagnostic Accuracy and Clinical Impact
by Rosa Alba Pugliesi, Karim Ben Mansour, Jonas Apitzsch, Angeliki Papachristodoulou, Vasileios Rafailidis and Douglas S. Katz
J. Clin. Med. 2025, 14(23), 8466; https://doi.org/10.3390/jcm14238466 - 28 Nov 2025
Viewed by 311
Abstract
Background/Objectives: To evaluate the diagnostic accuracy of artificial intelligence (AI)-based imaging techniques for liver fibrosis and metabolic dysfunction-associated steatotic liver disease (MASLD). Materials and Methods: We performed a comprehensive search in PubMed, Embase, Cochrane Library, and Web of Science until August 2025. [...] Read more.
Background/Objectives: To evaluate the diagnostic accuracy of artificial intelligence (AI)-based imaging techniques for liver fibrosis and metabolic dysfunction-associated steatotic liver disease (MASLD). Materials and Methods: We performed a comprehensive search in PubMed, Embase, Cochrane Library, and Web of Science until August 2025. A total of 15 studies (mean age of patients 56 years, 60% male) were included. The risk of bias in the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Diagnostic performance metrics were calculated using a random-effects bivariate model, including the area under the curve (AUC), sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio. Meta-regression analysis was conducted to investigate potential sources of heterogeneity when I2 was ≥50%. A p-value < 0.05 was considered statistically significant. Results: For liver fibrosis, pooled sensitivity was 0.85, specificity was 0.81, and AUC was 0.92. For MASLD, sensitivity was 0.86, specificity was 0.95, and AUC was 0.99. Different imaging modalities and AI classifiers caused significant study heterogeneity. To avoid misleading pooled estimates across varied datasets, imaging modality and AI model subgroup analyses were performed. Only three studies were used to estimate MASLD; therefore, considerable between-study heterogeneity should be considered. Conclusions: AI-based imaging modalities demonstrate promising diagnostic accuracy for liver fibrosis and MASLD, warranting further standardization to enhance diagnostic consistency. Full article
(This article belongs to the Special Issue Recent Clinical Research on Nonalcoholic Fatty Liver Disease: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop